louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06943638: How Easy-to-Follow Exercises Can Help Cancer Patients With Anxiety While Receiving Chemotherapy
Official title: The Effect of Mild Exercise While Receiving Chemotherapy on the Psychology of the Cancer Patient
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Exercise
Stress
Keywords: cancer
physiotherapy
exercise
physical therapy
chemotherapy
stress
Lead sponsor: University of Crete
Sponsor class: OTHER
First posted: 2025-04-24
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Cancer is one of the main causes of death, and this study looks at how light exercise and stretching might reduce anxiety in patients receiving chemotherapy. The research took place in a hospital's daily care unit and used a study design where each patient was compared to themselves, measuring anxiety before and after the exercise program.


Eligibility criteria: Inclusion Criteria:

* Adult patients (\>18 years old) with cancer receiving chemotherapy
* Signed patient consent

Exclusion Criteria:

* The denial of the patient
* The occurrence of side effects from the treatment (such as dizziness, nausea, severe fatigue)
* Patients with low cognitive level where they could not follow simple instructions
* Patients with hearing disorders that prevented them from following simple instructions
* Patients who could not mobilize independently.

Primary outcomes:
measure: The change in the anxiety assessment scale (STAI-State) for cancer patients receiving chemotherapy doing mild exercises and stretches
timeFrame: Baseline
measure: The change in the anxiety assessment scale (STAI-State) for cancer patients receiving chemotherapy doing mild exercises and stretches
timeFrame: Post-intervention, approximately 20 minutes from baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Athens
country: Greece
facility: General Oncological Hospital of Kifisia Oi Agioi Anargyroi
state: Kifissia
Study officials:
References:
citation: Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016 Sep 21;9(9):CD005001. doi: 10.1002/14651858.CD005001.pub3.
citation: Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112.
Clinical trial NCT06665438: Dexmedetomidine and Bupivacaine Intra-articular for Postoperative Analgesia After Knee Arthroscopic Surgery
Official title: Impact of Dexmedetomidine Add to Intra-articular Bupivacaine for Post Operative Analgesia After Knee Arthroscopic Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Post Operative Analgesia
Keywords: Knee arthroscopy
Bupivacaine
Dexmedetomidine
Postoperative pain
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-10-30
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: patients randomly allocate to one of three groups (n =25) for intra articular injection using Sealed envelope method as follows: Group (C), receive 18 ml saline only and serve as the control group(C). Group (B) receive 18ml 0.25% bupivacaine. Group(D)received 18 ml 0.25% bupivacaine and dexmedetomidine 1 μg/kg, the study drugs will injected in the knee joint by the surgeon through the arthroscope after completing the procedure (without knowing the drugs used)
Primary purpose: TREATMENT

Brief summary: The aim of this study to compare the analgesic effects of intraarticular dexmedetomidine added to bupivacaine with those of bupivacaine alone after knee arthroscopy

Detailed description: prospective double-blind study perform on 75 patients candidates for anterior cruciate ligament (ACL) reconstruction by knee arthroscopy refer to the clinic of Al Azhar University Hospital, Assiut, Egypt, to evaluate the effect of adding dexmedetomidine to intra articular bupivacaine injection on postoperative pain after knee arthroscopy.

Eligibility criteria: Inclusion Criteria:

* ASA I-II patients
* Either sex
* Aged 18-65 years
* Candidates for anterior cruciate ligament (ACL) reconstruction by knee arthroscopy
* Exclusion Criteria:
* the patients with kidney failure, liver failure, valvular and ischemic heart disease , high blood pressure, diabetes, history of infection and malignancy.
* history of coagulation diseases, and history of drug allergies to used drugs.
* those who consumed NSAIDs and analgesics 24 h before surgery were excluded from the study.

Primary outcomes:
measure: Change on the visual analog scale (VAS) for pain (0 = no pain to 100 = the maximum pain )to assessment the duration of analgesia following the surgery
timeFrame: post operative at 30 minute, 1 hour, 2 hour, 4 hour, 6 hour, 12 hour, and 24 hour .
Secondary outcomes:
measure: Total meperidine consumption . Meperidine will be used intravenously if the visual analog scale ( VAS) score was >50 to control postoperative pain.
timeFrame: The total dose of meperidine given between the study groups during the first 24 hour( post operative at 30 minute, 1 hour, 2 hour, 4 hour, 6 hour, 12 hour, and 24 hour),will be recorded.
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Al-Azhar University
city: Assiut
country: Egypt
facility: Al-Azhar University
Study officials:
References:
Clinical trial NCT01326338: Nitazoxanide for the Treatment of Prolonged Diarrhea in Children
Official title: Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Prolonged Diarrhea in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diarrhea
Keywords: Diarrhea
Lead sponsor: Romark Laboratories L.C.
Sponsor class: INDUSTRY
First posted: 2011-03-30
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine the efficacy of nitazoxanide suspension compared to placebo in treating prolonged diarrhea in children.


Eligibility criteria: Inclusion Criteria:

* Patients with diarrhea ≥3 days but \<30 days duration.
* No visible blood in stool.

Exclusion Criteria:

* Use of any antibacterial, antiparasitic or antiviral drugs within 5 days of enrollment.
* Females who are pregnant, suspected of being pregnant or breastfeeding.
* Serious systemic disorders incompatible with the study.
* History of hypersensitivity to nitazoxanide.
* Patients in whom the possibility of receiving placebo and not being able to receive immediately an effective treatment will be incompatible with the severity of the patient's illness according to the investigator's judgment.
* Patients known to have or suspected of having AIDS or other immune deficiencies.

Primary outcomes:
measure: Time from first dose to resolution of symptoms
timeFrame: Up to 17 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cajamarca
country: Peru
facility: Regional Hospital of Cajamarca
Study officials:
affiliation: Regional Hospital of Cajamarca
name: Nicolas Lopez, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rossignol JF, Lopez-Chegne N, Julcamoro LM, Carrion ME, Bardin MC. Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg. 2012 Mar;106(3):167-73. doi: 10.1016/j.trstmh.2011.11.007. Epub 2012 Jan 31.
Clinical trial NCT01533038: BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia
Official title: BPH-6: A UroLift® System Post Market Multi-Center Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Benign Prostatic Hyperplasia
Lead sponsor: NeoTract, Inc.
Sponsor class: INDUSTRY
First posted: 2012-02-15
Enrollment: 80
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with each therapy.

Detailed description: The study is a prospective, consecutive, multi-center, 1:1 randomized study (UroLift System:TURP). The study is intended to be conducted at up to 20 different centers in Europe and Canada to enroll up to 100 subjects.

Subject follow-up visits are at 2 weeks, 1, 3, 6, 12 and 24 months for all subjects.

Eligibility criteria: Inclusion Criteria:

• Men \>50 years old with moderate-severe BPH

Exclusion Criteria:

* Size, width of prostate
* Other medical condition or co-morbidity contraindicative for TURP or UroLift

Primary outcomes:
measure: Responder Analysis: A Subject is a Responder at the 12 Month Follow-up Time Point if All 6 Thresholds of the BPH-6 Endpoint Are Met
timeFrame: Month 12
Secondary outcomes:
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Herlev Hospital
city: Cologne
country: Germany
facility: PAN Klinik
city: Freiburg
country: Germany
facility: University Hospital Freiburg
city: Munich
country: Germany
facility: Ludwigs-Maximilians Universität / Klinikum Großhadern
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
city: Frimley
country: United Kingdom
facility: Frimley Park Hospital
city: Sheffield
country: United Kingdom
facility: The Royal Hallamshire Hospital
city: Sunderland
country: United Kingdom
facility: City Hospitals Sunderland NHS Foundation Trust
city: Taunton
country: United Kingdom
facility: Musgrove Park Hospital
Study officials:
affiliation: University Vita Salute San Raffaele
name: Francesco Montorsi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015 Oct;68(4):643-52. doi: 10.1016/j.eururo.2015.04.024. Epub 2015 Apr 30.
Clinical trial NCT00312338: Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Official title: Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bacterial Conjunctivitis
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
Collaborators: name: Tufts University
First posted: 2006-04-10
Enrollment: 137
Sex: ALL
Minimum age (years): 1
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora


Eligibility criteria: Inclusion Criteria:

* Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in either or both eyes (for \< 3 days duration) based on clinical observation; matched healthy controls

Exclusion Criteria:

* Cannot have had bacterial conjunctivitis symptoms as reported by parent for \> 2 days

Primary outcomes:
measure: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation
timeFrame: Day 0 and Day 42
measure: Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation
timeFrame: Day 0, Day 42
measure: Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation
timeFrame: Day 0, Day 42
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Multiple Locations
state: Texas
Study officials:
affiliation: Investigator / Contact
name: Steven J. Lichtenstein, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00629538: Therapeutic Thoracentesis for Patients With Congestive Heart Failure and Large Pleural Effusion
Official title: Effect of Therapeutic Thoracentesis on Cardiopulmonary Function in Patients With Congestive Heart Failure Complicated With Large to Massive Pleural Effusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congestive Heart Failure
Transudative Pleural Effusion
Keywords: congestive heart failure
thoracentesis
transudative pleural effusions
Lead sponsor: Taipei Medical University Hospital
Sponsor class: OTHER
First posted: 2008-03-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Transudative pleural effusions are a common manifestation of patients with congestive heart failure. Severe dyspnea and respiratory failure may develop in those with large effusions, which in general show poor response to medical treatment. Therapeutic thoracenteses (TT) may be indicated in these patients and can produce marked relief of symptoms. However, the underlying effect of TT on gas exchange and respiratory mechanics in theses patients remains unclear. The researchers' hypothesis is that,TT may improve arterial oxygenation and respiratory mechanics in patients with congestive heart failure complicated by large pleural effusions.


Eligibility criteria: Inclusion Criteria:

* transudative pleural effusion established by the criteria of Light
* the effusion occupying at least half of one hemithorax shown on chest radiography
* symptoms of respiratory distress
* diagnosis of congestive heart failure

Exclusion Criteria:

* severe uncontrolled coagulopathy
* unstable hemodynamics
* diagnosis of liver cirrhosis, chronic obstructive pulmonary disease,asthma and/or any parenchymal lung disease, such as pneumonia, fibrosis or malignancy.

Primary outcomes:
measure: Vital signs, minute volume, expiratory tidal volume, dynamic compliance, arterial oxygen saturation and arterial blood gases, the volume of pleural fluid removed, and the changes in pleural liquid pressure and pleural space elastance
timeFrame: 15 minutes after therapeutic thoracentesis
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University Hospital
Study officials:
affiliation: Department of Internal Medicine, Taipei Medical University Hospital
name: Chi-Li Chung, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chen WL, Chung CL, Hsiao SH, Chang SC. Pleural space elastance and changes in oxygenation after therapeutic thoracentesis in ventilated patients with heart failure and transudative pleural effusions. Respirology. 2010 Aug;15(6):1001-8. doi: 10.1111/j.1440-1843.2010.01812.x. Epub 2010 Jul 20.
Clinical trial NCT01340638: Seal Pressure With Classical Laryngeal Mask and Cookgas Mask in Adult Patients
Official title: EFFECTIVENESS OF SEAL PRESSURE IN AIRWAY OF THE CLASSIC LARYNGEAL MASK AND THE COOKGAS LARYNGEAL MASK IN ADULT PATIENTS UNDERGOING SURGERY IN AMBULATORY SETTINGS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Seal Pressure
Keywords: Seal pressure
Cookgas
AirQ
LMA
supraglottic device
Lead sponsor: Universidad de Antioquia
Sponsor class: OTHER
Collaborators: name: Grupo de via aerea dificil universidad de antioquia
First posted: 2011-04-22
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The working hypothesis in this study is that the supraglottic device COOKGAS provides seal pressure as well or better than LMAc ™ when adult patients undergoing outpatient surgery, are sommeted to both interventions.


Eligibility criteria: Inclusion Criteria:

* Over 18 years
* Patient ASA I, II and III
* Complete fast
* Ambulatory Surgery
* Time less than two hours surgically
* Supine Surgery
* Acceptance of informed consent

Exclusion Criteria:

* No acceptance of informed consent
* Pregnancy or breastfeeding
* Hemostatic alterations
* Abdominal surgery
* History of gastrointestinal reflux
* BMI over 35
* Mouth opening less than 1.5 cm
* Airway abnormalities
* Surgery in respiratory tract

Primary outcomes:
measure: Seal pressures
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
city: Medellin
country: Colombia
facility: Ips Universitaria
state: Antioquia
Study officials:
affiliation: Universidad de Antioquia
name: IVAN D ARENAS, ANESTHETIST
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05353608: Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients.
Official title: Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: a Multicenter Observational Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
COVID-19
Keywords: Lung scintigraphy
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2022-04-29
Enrollment: 183
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COVID-19 patients who underwent lung scintigraphy for suspected PE.

Brief summary: A frequent complication of COVID-19 disease is pulmonary embolism (PE).

Lung ventilation/perfusion (V/P) scintigraphy is a well-established test for PE diagnosis. The test is interpreted based on the recognition of wedge shaped perfusion mismatched defects. However, the ventilation procedure increases the potential risk of contamination by the aerosol secretion and the expired air.

A variety of strategies have been proposed in the nuclear medicine literature regarding performance of lung ventilation scintigraphy in COVID-19 patients with suspected acute PE. However, there is currently no factual data in this specific population to support recommendations to the nuclear medicine community.

The aim of this study was to assess the role of ventilation imaging when performing lung scintigraphy for suspected PE in COVID-19 patients.


Eligibility criteria: Inclusion Criteria:

* Patients with suspected COVID-19 disease
* Referred for lung scintigraphy for suspected acute PE

Exclusion Criteria:

* Patient under guardianship or curatorship
* Patient deprived of liberty by an administrative or judicial decision
* Inability or refuse to give consent

Primary outcomes:
measure: PE diagnosis on lung scintigraphy without the ventilation scan.
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
city: Clermont-Ferrand
country: France
facility: Cnetre Jean-Perrin
Study officials:
References:
Clinical trial NCT04558008: Effectiveness of MBSR Among Teachers at Upper Secondary Schools and Schools of Health and Social Care
Official title: Effectiveness of Online Mindfulness-based Stress Reduction Among Teachers at Upper Secondary Schools and Schools of Health and Social Care
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stress Reduction
Mental Well-being
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2020-09-22
Enrollment: 76
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim is to evaluate the effectiveness of online Mindfulness-based Stress Reduction among school teachers in Danish upper secondary schools and schools of health and social care on mental well-being in the teachers and their students. The study is a cluster-randomised trial including 43 schools; 76 teachers; 1.000 students.


Eligibility criteria: Inclusion Criteria:

* School teacher at a Danish upper secondary school or school of health and social care that commit to participate in a trial aiming to implement and evaluate the effectiveness of a school-based mindfulness programme.

Exclusion Criteria:

* acute treatment-demanding clinical depression or a diagnosis of psychosis or schizophrenia
* abuse of alcohol, drugs, medicine

Primary outcomes:
measure: Perceived Stress Scale
timeFrame: 6 months from baseline
Secondary outcomes:
measure: Perceived Stress Scale
timeFrame: post MBSR (8 weeks from baseline) and 12 months from baseline
measure: Brief Resilience Scale
timeFrame: post MBSR (8 weeks from baseline), 6 and 12 months from baseline
measure: Symptom Check List - 5
timeFrame: post MBSR (8 weeks from baseline), 6 and 12 months from baseline
measure: WHO-5
timeFrame: post MBSR (8 weeks from baseline), 6 and 12 months from baseline
measure: Five Facet Mindfulness Questionnaire-15
timeFrame: post MBSR (8 weeks from baseline), 6 and 12 months from baseline
measure: Amsterdam Resting State Questionnaire
timeFrame: post MBSR (8 weeks from baseline), 6 and 12 months from baseline
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Danish Center for Mindfulness
Study officials:
affiliation: Aarhus University, Danish Center for Mindfulness
name: Lone Fjorback, PhD, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04090008: A Randomized Trial on Platelet Rich Plasma Versus Saline Dressing of Diabetic Foot Ulcers
Official title: A Randomized Controlled Trial on Platelet Rich Plasma Gel Compared to Normal Saline Dressing of Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Foot
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2019-09-16
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: New treatments for persistent DFU have emerged, among which are the bioengineered skin substitutes, extracellular matrix proteins products, matrix metalloproteinases modulators, and growth factor therapy. Platelet rich plasma (PRP) gel has been used for stimulating wound healing since the last decade of the 20th century. This randomized trial was conducted to assess the role of PRP in gel form as a treatment for clean non-healing diabetic foot ulcer in comparison to regular dressing with saline as a control.


Eligibility criteria: Inclusion Criteria:

* adult patients of both sexes aging below 70 years with non-infected chronic foot ulcer confined to one anatomical site. Chronicity was defined as non-healing ulcer for twelve or more weeks

Exclusion Criteria:

* Patients with chronic limb ischemia.
* Evidence of osteomyelitis in the affected foot
* Exposed tendons, ligaments or bones at the base of ulcer
* Patients who received radiotherapy or chemotherapy at time of study or within 3 months of its beginning.
* Patients having low peripheral platelet count, low serum albumin level or low hemoglobin level

Primary outcomes:
measure: Percent reduction in the ulcer size
timeFrame: 20 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mansourah
country: Egypt
facility: Mansoura university hospital
state: Dakahlia
Study officials:
affiliation: Mansoura University
name: Sameh Emile, M.D.
role: PRINCIPAL_INVESTIGATOR
References: